Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31546727 | 0.89 | CRBN (0.49) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL31546820 | 0.86 | CRBN (0.48) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL31546779 | 0.85 | CRBN (0.48) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL31546850 | 0.84 | IKZF2 (0.48) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL31546828 | 0.82 | CRBN (0.49) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL31546910 | 0.82 | CRBN (0.51) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL31546794 | 0.81 | CRBN (0.49) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL31546864 | 0.80 | CRBN (0.48) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL31546925 | 0.79 | IKZF2 (0.48) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL31546770 | 0.79 | CRBN (0.58) | CRBNIKZF2CSNK1A1IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076285-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |